<code id='7F4CC27288'></code><style id='7F4CC27288'></style>
    • <acronym id='7F4CC27288'></acronym>
      <center id='7F4CC27288'><center id='7F4CC27288'><tfoot id='7F4CC27288'></tfoot></center><abbr id='7F4CC27288'><dir id='7F4CC27288'><tfoot id='7F4CC27288'></tfoot><noframes id='7F4CC27288'>

    • <optgroup id='7F4CC27288'><strike id='7F4CC27288'><sup id='7F4CC27288'></sup></strike><code id='7F4CC27288'></code></optgroup>
        1. <b id='7F4CC27288'><label id='7F4CC27288'><select id='7F4CC27288'><dt id='7F4CC27288'><span id='7F4CC27288'></span></dt></select></label></b><u id='7F4CC27288'></u>
          <i id='7F4CC27288'><strike id='7F4CC27288'><tt id='7F4CC27288'><pre id='7F4CC27288'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:Wikipedia    Page View:33
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In